<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114972</url>
  </required_header>
  <id_info>
    <org_study_id>S2024</org_study_id>
    <secondary_id>90169394</secondary_id>
    <nct_id>NCT00114972</nct_id>
  </id_info>
  <brief_title>SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries</brief_title>
  <acronym>SYNTAX</acronym>
  <official_title>SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardialysis BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SYNTAX trial is designed to determine the best treatment for patients with complex
      coronary disease (blocked or narrowed arteries in both the right and left sides of the heart)
      by randomizing patients to receive either percutaneous coronary intervention (PCI) with
      polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the introduction of drug-eluting stents (DESs) and to improvements in therapy for both
      percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) patients,
      PCI is challenging CABG as the gold standard for treatment of three vessel (3VD) and left
      main (LM) coronary disease.

      SYNTAX is a novel, randomized trial with nested registries comparing PCI with
      paclitaxel-eluting TAXUS stents to CABG for 3VD and LM patients to evaluate the best
      treatment for these patients with complex coronary disease.

      Patients at participating centers will be evaluated by both a cardiothoracic surgeon and by
      an interventional cardiologist.

      Those patients who are determined to be eligible for treatment by both PCI and CABG will be
      randomized to receive either PCI with a polymer-based paclitaxel-eluting TAXUS stent or CABG.

      Patients who are determined to be unsuitable for treatment by PCI will be treated by CABG and
      will be entered into a CABG registry to help define the patient population in which stenting
      continues to be an unacceptable treatment option.

      Similarly, patients who are determined to be unsuitable for treatment by CABG will be treated
      by PCI, using any interventional techniques or devices with or without the use of DES, and
      entered into a PCI registry to help define the patients for whom CABG is considered
      inappropriate.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Clinical Endpoint of 12-Month Binary MACCE.</measure>
    <time_frame>12 months post enrollment</time_frame>
    <description>Number of participants at primary clinical endpoint of 12-Month binary MACCE. MACCE is defined as: all cause death, cerebrovascular event (stroke), cocumented myocardial infarction, repeat revascularization (PCI and/or CABG).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-month Composite Safety Endpoint.</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>Number of participants at 12-month composite safety endpoint. Composite safety endpoint combines: all cause death, cerebrovascular event (stroke), and documented myocardial infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Repeat Revascularization (PCI and/or CABG).</measure>
    <time_frame>12 Months post enrollment</time_frame>
    <description>Number of participants with repeat revascularization (PCI and/or CABG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.</measure>
    <time_frame>1 month after procedure and 6 months, 3 years, and 5 years post allocation</time_frame>
    <description>Number of participants with Overall MACCE at 1 month post-procedure and at 6 months, 3 years, and 5 years post-allocation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of MACCE at 1 Month Post-procedure.</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>Number of participants with individual components of MACCE at 1 month post-procedure. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of MACCE at 6 Months Post-allocation.</measure>
    <time_frame>6 months post allocation</time_frame>
    <description>Number of participants with individual components of MACCE at 6 months post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of MACCE at 1 Year Post-allocation.</measure>
    <time_frame>1 year post allocation</time_frame>
    <description>Number of participants with individual components of MACCE at 1 year post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From MACCE and Its Components at 1 Year Post-allocation.</measure>
    <time_frame>1 year post allocation</time_frame>
    <description>Number of participants with freedom from MACCE and its components at 1 year post-allocation. Freedom from MACCE is defined as no MACCE nor any of the individual components of MACCE (all cause death, stroke, documented myocardial infarction, repeat revascularization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From MACCE and Its Components at 3 Years Post-allocation</measure>
    <time_frame>3 years post allocation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From MACCE and Its Components at 5 Years Post-allocation</measure>
    <time_frame>5 years post allocation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at 1 Month Post-procedure and at 6 Months, 1, 3 and 5 Years Post-allocation</measure>
    <time_frame>1 month after procedure and 6 months, 1, 3 and 5 years post allocation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost and Cost-effectiveness at 1, 3 and 5 Years Post-allocation</measure>
    <time_frame>1 year, 3 and 5 years post allocation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Characteristics (Including Co-morbidity and Coronary Vascular Lesion Complexity Scoring Referred to as the SYNTAX Score) of the Following: PCI Versus CABG Randomized Cohort, PCI Registry Cohort (CABG Ineligible), CABG Registry Cohort (PCI Ineligible)</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1800</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PCI with DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG (coronary artery bypass graft)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary Artery Bypass Graft</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent</intervention_name>
    <description>Drug Eluting Stent</description>
    <arm_group_label>PCI with DES</arm_group_label>
    <other_name>Percutaneous coronary intervention</other_name>
    <other_name>Paclitaxel eluting stent</other_name>
    <other_name>3 vessel disease</other_name>
    <other_name>Left main stem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary Artery Bypass Surgery</intervention_name>
    <description>Coronary Artery Bypass Surgery</description>
    <arm_group_label>CABG (coronary artery bypass graft)</arm_group_label>
    <other_name>Coronary artery disease</other_name>
    <other_name>Coronary artery bypass graft</other_name>
    <other_name>Left Main coronary artery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Three-vessel disease, left main disease or LM equivalent with or without 1, 2 or 3VD
             (left anterior descending [LAD], left circumflex [LCX], right coronary artery [RCA]
             territory)

          -  De novo lesions with at least 50% stenosis

          -  Myocardial ischemia (stable, unstable, silent)

        Exclusion Criteria:

          -  Prior PCI or CABG

          -  Acute myocardial infarction (with creatinine kinase &gt;2x upper limit of normal)

          -  Concomitant cardiac valve disease requiring surgical therapy (reconstruction or
             replacement)

          -  Participation or planned participation in another cardiovascular clinical study before
             1 year follow-up is completed

          -  Inability to give informed consent due to mental condition, mental retardation, or
             language barrier
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick W. Serruys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus University Medical Center Rotterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedrich W Mohr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monika Hanisch, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cardiovascular Research</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munroe Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Heart Institue</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Cardiology Research Foundation (St. Anthony's Medical Center)</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61108-2465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Hospital</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Research Institute</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesys Regional Medical Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac &amp; Vascular Research Center of Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Stony Brook School of Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SJH Cardiology Associates</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Health Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular and Thoracic Surgeons of Greensboro</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Endovascular Heart Institue</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital 1st Fl</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik für Herzchirurgie Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus AKH</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hôpital Universitaire Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>CZ-100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interni Klinika VFN</name>
      <address>
        <city>Praha</city>
        <zip>CZ-128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>D-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Helsinki Meilahti Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cardiovasculaire Paris Sud - Massy</name>
      <address>
        <city>Massy</city>
        <zip>F-91349</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopital Universitaire Rouen - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Hilaire Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hôpital Universitaire Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Charite Berlin, Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Virchow Klinikum Herzkatheterlabor</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Luebeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern</name>
      <address>
        <city>München</city>
        <zip>D-81337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>D-54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical School of University PECS</name>
      <address>
        <city>Pecs</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Fisiologia Clinica, Stabilimento di Massa Ospedale</name>
      <address>
        <city>Massa</city>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Mirano</name>
      <address>
        <city>Mirano</city>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken, De Weezenlanden</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia - Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University of Cardiology</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Marta</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Y Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>ES-08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>ES-28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-22181</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitets Sjukhuset - Stockholm</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital London</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Infirmary Oxford II</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2005</study_first_submitted>
  <study_first_submitted_qc>June 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2005</study_first_posted>
  <results_first_submitted>March 27, 2009</results_first_submitted>
  <results_first_submitted_qc>May 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2010</results_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nic Van Dyck</name_title>
    <organization>Boston Scientific</organization>
  </responsible_party>
  <keyword>Three-vessel coronary artery disease</keyword>
  <keyword>Left main coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CABG</title>
          <description>Coronary Artery By-pass Graft (CABG)</description>
        </group>
        <group group_id="P2">
          <title>PCI With DES</title>
          <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="897"/>
                <participants group_id="P2" count="903"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="849"/>
                <participants group_id="P2" count="891"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CABG</title>
          <description>Coronary Artery By-pass Graft (CABG)</description>
        </group>
        <group group_id="B2">
          <title>PCI With DES</title>
          <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="897"/>
            <count group_id="B2" value="903"/>
            <count group_id="B3" value="1800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="400"/>
                    <measurement group_id="B2" value="397"/>
                    <measurement group_id="B3" value="797.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="497"/>
                    <measurement group_id="B2" value="506"/>
                    <measurement group_id="B3" value="1003.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.96" spread="9.79"/>
                    <measurement group_id="B2" value="65.23" spread="9.66"/>
                    <measurement group_id="B3" value="65.09" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="708"/>
                    <measurement group_id="B2" value="690"/>
                    <measurement group_id="B3" value="1398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="245.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="267.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="197.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="208.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="148.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="179.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angina</title>
          <description>number of particpiants with stable, unstable, or no angina at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with Stable Angina at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="513"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="1027.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Unstable Angina at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="512.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Silent Ischemia at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="148.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with No Angina at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="113.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bifurcation lesion (per participant)</title>
          <description>Number of participants with at least one bifurcation lesion as determined by the angiographic core laboratory on the baseline angiogram</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>One or more Bifurcated Lesion(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="652"/>
                    <measurement group_id="B2" value="649"/>
                    <measurement group_id="B3" value="1301.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Bifurcated Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="499.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure ≥130/85 mmHg</title>
          <description>number of participants with blood pressure equal or higher than 130/85mmHg</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Blood Pressure &gt;= 130/85 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="574"/>
                    <measurement group_id="B2" value="622"/>
                    <measurement group_id="B3" value="1196.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Pressure &lt;130/85 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="323"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="604.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carotid artery disease</title>
          <description>number of particpants with diagnosed carotid artery disease at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diagnosed Carotid Artery Disease at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="148.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Diagnosed Carotid Artery Disease at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="822"/>
                    <measurement group_id="B2" value="830"/>
                    <measurement group_id="B3" value="1652.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive heart failure</title>
          <description>number of particpants with congestive heart failure at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Congestive Heart Failure at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Congestive Heart Failure at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="850"/>
                    <measurement group_id="B2" value="867"/>
                    <measurement group_id="B3" value="1717.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoking</title>
          <description>Number of participants that were smoking at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smokers at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="363.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smokers at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="701"/>
                    <measurement group_id="B2" value="736"/>
                    <measurement group_id="B3" value="1437.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <description>All participants with diagnosed diabetes at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diagnosed Diabetes at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="511.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Diagnosed Diabetes at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="641"/>
                    <measurement group_id="B2" value="648"/>
                    <measurement group_id="B3" value="1289.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL cholesterol (&lt;40 Male or &lt;50 Female)</title>
          <description>number of male participants with a high-density lipoprotein (HDL)&lt;40 and female particpants with a HDL&lt;50 determined by the central chemistry laboratory</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participant HDL Less Than Limit at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="404"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="783.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant HDL Greater Than Limit at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="524"/>
                    <measurement group_id="B3" value="1017.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperlipidemia</title>
          <description>participants with hyperlipidemia at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with Hyperlipidemia at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="686"/>
                    <measurement group_id="B2" value="705"/>
                    <measurement group_id="B3" value="1391.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants without Hyperlipidemia at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="409.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin requiring diabetes</title>
          <description>Number of participants with diabetes treated with insulin</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with Insulin dependent Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="182.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with non-Insulin independent Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="329.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nondiabetic Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="641"/>
                    <measurement group_id="B2" value="648"/>
                    <measurement group_id="B3" value="1289.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medically treated Diabetes</title>
          <description>Number of participants with medically treated diabetes.Excludes participants with diabetes treated with diet only.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetic Participants Medically Treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="452.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Participants Treated through Diet only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Diabetic Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="641"/>
                    <measurement group_id="B2" value="648"/>
                    <measurement group_id="B3" value="1289.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolic Syndrome</title>
          <description>number of participants that met the criteria of metabolic syndrome defined by the American Heart Association</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with a Metabolic Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="317"/>
                    <measurement group_id="B2" value="339"/>
                    <measurement group_id="B3" value="656.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants without a Metabolic Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="580"/>
                    <measurement group_id="B2" value="564"/>
                    <measurement group_id="B3" value="1144.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Poor LVEF</title>
          <description>number of participants with left ventricular ejection fraction &lt;30% at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>LVEF &lt;30% at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEF &gt;=30% at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="875"/>
                    <measurement group_id="B2" value="891"/>
                    <measurement group_id="B3" value="1766.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior MI</title>
          <description>Number of participants who had a myocardial infarction before baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Myocardial Infarction Before Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="585.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Myocardial Infarction Before Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="597"/>
                    <measurement group_id="B2" value="618"/>
                    <measurement group_id="B3" value="1215.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Stroke</title>
          <description>number of participants who had a stroke before baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stroke Prior to Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Stroke Prior to Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="854"/>
                    <measurement group_id="B2" value="868"/>
                    <measurement group_id="B3" value="1722.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior TIA</title>
          <description>number of partipants who had a Transient Ischemic Attack before baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Transient Ischemic Attack Before Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Transient Ischemic Attack before baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="852"/>
                    <measurement group_id="B2" value="864"/>
                    <measurement group_id="B3" value="1716.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Occlusion (per patient)</title>
          <description>Number of participants with at least one total occlusion as determined by the angiografic core laboratory on the baseline angiogram</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with at least One Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="415.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Partial Occlusion(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="699"/>
                    <measurement group_id="B2" value="686"/>
                    <measurement group_id="B3" value="1385.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride levels ≥150 mg/dL</title>
          <description>participants with Triglyceride levels ≥150 mg/dL as determined by a central chemistry laboratorium at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with Triglyceride Levels &gt;= 150 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="579.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Triglyceride Levels &lt;150 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="593"/>
                    <measurement group_id="B2" value="628"/>
                    <measurement group_id="B3" value="1221.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Additive Euroscore</title>
          <description>Additive EuroSCORE is a prognostic scoring system calculating predicted operative mortality for patients undergoing cardiac surgery; it has been the most rigorously evaluated scoring system in cardiac surgery. A predetermined weighted score is assigned for specified patient-, cardiac-, and operation-related factors; for example, pulmonary hypertension is assigned a score of 2. The sum of scores is the additive EuroSCORE. EuroSCORE is calculated from site reported baseline data. A score of greater than 6 is considered as being predictive of an increased mortality risk. (www.euroscore.org)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.79" spread="2.69"/>
                    <measurement group_id="B2" value="3.75" spread="2.62"/>
                    <measurement group_id="B3" value="3.77" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body Mass Index calculated from participants heigth and weight.</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.91" spread="4.54"/>
                    <measurement group_id="B2" value="28.11" spread="4.80"/>
                    <measurement group_id="B3" value="28.01" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lesions per partipant</title>
          <description>Average number of lesions per participant as determined by the investigator</description>
          <units>Number of lesions/Participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.99" spread="1.7"/>
                    <measurement group_id="B2" value="3.94" spread="1.66"/>
                    <measurement group_id="B3" value="3.97" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parsonnet Score</title>
          <description>The first scoring system in cardiac surgery to calculate mortality risk and to become popular was the Parsonnet risk stratification system, which was developed in the United States in the 1980s. A predetermined weighted score is assigned for several specified patient-, cardiac-, and operation-related factors; for example, dialysis is assigned a score of 10. A score of greater than 15 is considered as being predictive of an increased mortality risk. Parsonette score is calculated from baseline information.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.43" spread="6.84"/>
                    <measurement group_id="B2" value="8.53" spread="6.95"/>
                    <measurement group_id="B3" value="8.48" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Syntax Score</title>
          <description>The SYNTAX score characterizes the coronary vasculature. It combines the importance of a diseased coronary artery segment (Leaman score), adverse characteristics of a lesion (ACC/AHA lesion classification) and the modified Duke/ICPS classification for bifurcation lesions. Higher SYNTAX scores are indicative of more complex lesions and disease; thus higher scores would predict worse short-term outcomes. Calculated from angiographic corelab analysis of baseline angiogram. (www.syntaxscore.com)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="11.37"/>
                    <measurement group_id="B2" value="28.39" spread="11.46"/>
                    <measurement group_id="B3" value="28.7" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Clinical Endpoint of 12-Month Binary MACCE.</title>
        <description>Number of participants at primary clinical endpoint of 12-Month binary MACCE. MACCE is defined as: all cause death, cerebrovascular event (stroke), cocumented myocardial infarction, repeat revascularization (PCI and/or CABG).</description>
        <time_frame>12 months post enrollment</time_frame>
        <population>ITT analysis. Number of participants analyzed equals number of subjects who completed Overall Study, as listed in Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Clinical Endpoint of 12-Month Binary MACCE.</title>
          <description>Number of participants at primary clinical endpoint of 12-Month binary MACCE. MACCE is defined as: all cause death, cerebrovascular event (stroke), cocumented myocardial infarction, repeat revascularization (PCI and/or CABG).</description>
          <population>ITT analysis. Number of participants analyzed equals number of subjects who completed Overall Study, as listed in Participant Flow.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12-month Composite Safety Endpoint.</title>
        <description>Number of participants at 12-month composite safety endpoint. Composite safety endpoint combines: all cause death, cerebrovascular event (stroke), and documented myocardial infarction.</description>
        <time_frame>12 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>12-month Composite Safety Endpoint.</title>
          <description>Number of participants at 12-month composite safety endpoint. Composite safety endpoint combines: all cause death, cerebrovascular event (stroke), and documented myocardial infarction.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.</title>
        <description>Number of participants with Overall MACCE at 1 month post-procedure and at 6 months, 3 years, and 5 years post-allocation.</description>
        <time_frame>1 month after procedure and 6 months, 3 years, and 5 years post allocation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.</title>
          <description>Number of participants with Overall MACCE at 1 month post-procedure and at 6 months, 3 years, and 5 years post-allocation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACCE 1 month post procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACCE 6 months post procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of MACCE at 1 Month Post-procedure.</title>
        <description>Number of participants with individual components of MACCE at 1 month post-procedure. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
        <time_frame>1 month after procedure</time_frame>
        <population>ITT analysis</population>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of MACCE at 1 Month Post-procedure.</title>
          <description>Number of participants with individual components of MACCE at 1 month post-procedure. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
          <population>ITT analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="866"/>
                <count group_id="O2" value="895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All cause death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any repeat revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of MACCE at 6 Months Post-allocation.</title>
        <description>Number of participants with individual components of MACCE at 6 months post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
        <time_frame>6 months post allocation</time_frame>
        <population>ITT analysis</population>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of MACCE at 6 Months Post-allocation.</title>
          <description>Number of participants with individual components of MACCE at 6 months post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
          <population>ITT analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="860"/>
                <count group_id="O2" value="893"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All cause death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any repeat revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of MACCE at 1 Year Post-allocation.</title>
        <description>Number of participants with individual components of MACCE at 1 year post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
        <time_frame>1 year post allocation</time_frame>
        <population>ITT analysis</population>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Components of MACCE at 1 Year Post-allocation.</title>
          <description>Number of participants with individual components of MACCE at 1 year post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.</description>
          <population>ITT analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death any cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any repeat revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From MACCE and Its Components at 1 Year Post-allocation.</title>
        <description>Number of participants with freedom from MACCE and its components at 1 year post-allocation. Freedom from MACCE is defined as no MACCE nor any of the individual components of MACCE (all cause death, stroke, documented myocardial infarction, repeat revascularization).</description>
        <time_frame>1 year post allocation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From MACCE and Its Components at 1 Year Post-allocation.</title>
          <description>Number of participants with freedom from MACCE and its components at 1 year post-allocation. Freedom from MACCE is defined as no MACCE nor any of the individual components of MACCE (all cause death, stroke, documented myocardial infarction, repeat revascularization).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from any MACCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744"/>
                    <measurement group_id="O2" value="732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from any cause death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819"/>
                    <measurement group_id="O2" value="852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830"/>
                    <measurement group_id="O2" value="886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from documented MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="821"/>
                    <measurement group_id="O2" value="848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from any repeat revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="799"/>
                    <measurement group_id="O2" value="771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From MACCE and Its Components at 3 Years Post-allocation</title>
        <time_frame>3 years post allocation</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Repeat Revascularization (PCI and/or CABG).</title>
        <description>Number of participants with repeat revascularization (PCI and/or CABG).</description>
        <time_frame>12 Months post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CABG</title>
            <description>Coronary Artery By-pass Graft (CABG)</description>
          </group>
          <group group_id="O2">
            <title>PCI With DES</title>
            <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
          </group>
        </group_list>
        <measure>
          <title>Repeat Revascularization (PCI and/or CABG).</title>
          <description>Number of participants with repeat revascularization (PCI and/or CABG).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From MACCE and Its Components at 5 Years Post-allocation</title>
        <time_frame>5 years post allocation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life at 1 Month Post-procedure and at 6 Months, 1, 3 and 5 Years Post-allocation</title>
        <time_frame>1 month after procedure and 6 months, 1, 3 and 5 years post allocation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost and Cost-effectiveness at 1, 3 and 5 Years Post-allocation</title>
        <time_frame>1 year, 3 and 5 years post allocation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Characteristics (Including Co-morbidity and Coronary Vascular Lesion Complexity Scoring Referred to as the SYNTAX Score) of the Following: PCI Versus CABG Randomized Cohort, PCI Registry Cohort (CABG Ineligible), CABG Registry Cohort (PCI Ineligible)</title>
        <time_frame>5 Years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CABG</title>
          <description>Coronary Artery By-pass Graft (CABG)</description>
        </group>
        <group group_id="E2">
          <title>PCI With DES</title>
          <description>Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="391" subjects_at_risk="897"/>
                <counts group_id="E2" subjects_affected="357" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="897"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>coagulopathy, iron deficiency anaemia, leukocytosis, thrombocyopenia</sub_title>
                <description>Total of other events and subjects affected with these events in this organ system. Event terms are coagulopathy, iron deficiency anaemia, leukocytosis and thrombocyopenia. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="897"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="49" subjects_affected="30" subjects_at_risk="897"/>
                <counts group_id="E2" events="95" subjects_affected="74" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="38" subjects_affected="30" subjects_at_risk="897"/>
                <counts group_id="E2" events="85" subjects_affected="66" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Arrhythmia, other rare cardiac disorders</sub_title>
                <description>Rare cardiac disorders like ventricular arrhytmias, atrioventricular blocks, cardiomyopathy, valve disease, coronary artery dissection and occlusion. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="58" subjects_affected="51" subjects_at_risk="897"/>
                <counts group_id="E2" events="99" subjects_affected="82" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="47" subjects_affected="45" subjects_at_risk="897"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="897"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="897"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="897"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="897"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="897"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="897"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="897"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Coronary Artery Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="897"/>
                <counts group_id="E2" events="41" subjects_affected="28" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="897"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="897"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="897"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="897"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract, lens disorder, renal detachment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="897"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="897"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Other gastrointestinal disorders</sub_title>
                <description>Sum of all other gastrointestinal disorders like ulcers, pain, hernia, obstructions, vomiting, nausea, etc. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="897"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="897"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="897"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Other general disorders and administration site conditions</sub_title>
                <description>Other general disorders mainly related to catheter site events like pain, haemorrhage and pyrexia, multi-organ failure, wound healing problems. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="897"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <description>Total of hepatobiliary disorders like bile duct stone, cholecystitis, hepatic failure and hepatic function abnormal.Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="897"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock , reaction and drug hypersensitivity</sub_title>
                <description>Total of events related to immune system disorder like anaphylactic reaction or shock and drug hypersensitivity. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="897"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and abcess</sub_title>
                <description>Total of any other infection or abcess. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="45" subjects_affected="44" subjects_at_risk="897"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="897"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="897"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="897"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury and procedural complications</sub_title>
                <description>Total of all other procedural complications and injuries. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="897"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="897"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="897"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal blood test values</sub_title>
                <description>Total of all abnormal blood tests (increased or decreased) and abnormal diagnostic procedures. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="897"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="897"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Total of all metabolism and nutrition disorders like hyper- and hypoglycaemie, hypokalaemia, hyponatraemia, dehydration, etc. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="897"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue diorders</sub_title>
                <description>Total of musculoskeletal and connective tissue disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="897"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <description>Total of neoplasms, benign, malignant and unspecified. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="897"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="897"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <description>Total of all other nervous system disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="897"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>Total of all psychiatric disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="897"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Total of all other renal and urinary disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="897"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="897"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic disorders</sub_title>
                <description>Total of all reproductive system and breast disorders. All events in this system were related to prostatic disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="897"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="897"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="897"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="897"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="897"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Total of all other respiratory, thoracic and mediastinal disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="897"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin and subcutaneous tissue disorders</sub_title>
                <description>Total of skin and subcutaneous tissue disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="897"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <description>Total of surgical and medical procedures. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="897"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <description>Total of vascular disorders. Occurrence of each individual event term is less than 1%.</description>
                <counts group_id="E1" events="48" subjects_affected="45" subjects_at_risk="897"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="509" subjects_at_risk="897"/>
                <counts group_id="E2" subjects_affected="405" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="109" subjects_affected="104" subjects_at_risk="897"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="897"/>
                <counts group_id="E2" events="70" subjects_affected="61" subjects_at_risk="903"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="129" subjects_affected="123" subjects_at_risk="897"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All other Adverse Events</sub_title>
                <description>Total of all other adverse events with an occurrence below the 5% treshold.</description>
                <counts group_id="E1" events="1099" subjects_affected="509" subjects_at_risk="897"/>
                <counts group_id="E2" events="854" subjects_affected="405" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="58" subjects_affected="56" subjects_at_risk="897"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" events="52" subjects_affected="47" subjects_at_risk="897"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="55" subjects_affected="54" subjects_at_risk="897"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="903"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nic Van Dyck / Senior Program Manager</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+ 31 43 356 8328</phone>
      <email>vandyckn@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

